Metastatic colorectal cancer (CRC) is one of the leading causes of cancer death in Western countries ([@bib37]). Although the overall 5-year survival from CRC is ∼60% in population-based series, prognosis is well established to be strongly linked to stage at presentation. However, there is variation in the prognosis for patients with the same-stage disease; hence, it is highly desirable to have additional markers more strictly related to the individual behaviour of the CRC in order to better individualise therapy. Such markers may serve as the basis for clinical trials to further improve the survival of patients with CRC, as well as avoid the unnecessary use of adjuvant treatment.

Four-and--a-half LIM domains protein 2 (FHL2), also known as downregulated in rhabdomyosarcoma LIM protein, is the second member of a small family of five proteins with four-and-a-half LIM domains ([@bib12]). This domain is a specialised double zinc-finger protein motif that has versatile cellular roles as regulators of gene expression, cyto-architecture, cell adhesion, cell motility, and signal transduction ([@bib33]; [@bib22]; [@bib21]). The acronym LIM is derived from the names of three transcription factors, Lin-11, Isl-1, and Mec-3, in which such a domain was first identified ([@bib21]).

Four-and-a-half LIM domains protein 2 is expressed in many normal human tissues such as the heart, ovary, kidney, prostate, testis, small intestine, and colon ([@bib12]; [@bib3]; [@bib35]). The protein is intriguing because it can function as either an activator or repressor of target proteins in a cell type-dependent fashion. It functions also as a coactivator of many transcription factors, such as *β*-catenin, activator protein-1, CRE-binding protein and extracellular signal-regulated kinase 2 ([@bib29]; [@bib42]; [@bib21]); and as a corepressor of the promyelocytic leukaemia zinc-finger protein in muscle cells ([@bib28]).

Four-and-a-half LIM domains protein 2 has been identified as an oncoprotein in several types of cancer. The mRNA level of FHL2 is elevated in both low- and high-grade glioma, and overexpression of FHL2 stimulates the proliferation, anchorage-independent growth, and migration of human glioblastoma cells ([@bib26]). Nuclear localisation of FHL2 is associated with recurrence in prostate cancer ([@bib23]). Low FHL2 expression is related to better survival in patients with breast cancer ([@bib10]). Four-and-a-half LIM domains protein 2 is highly expressed in human colon cancer, and cell line experiments showed that FHL2 is critical for migration and invasion ([@bib45]). Moreover, suppression of FHL2 in colon cancer cell lines induces cell differentiation and inhibits tumorigenesis ([@bib40]).

In the present study, we aimed to investigate a possible prognostic role of FHL2 expression in a large series of CRC cases, without evidence of distant metastasis at the time of presentation; development of metastases and mortality are the outcome parameters. We thereby focus on expression of FHL2 in neoplastic epithelial cells.

Materials and methods
=====================

Patients
--------

We retrospectively analysed tumour samples from consecutive patients who underwent surgical resection of a primary CRC, without evidence of distant metastasis at the time of surgery. All patients underwent surgical resection at the Erasme University Hospital (Brussels, Belgium) between May 1990 and December 2000. Sex, age and pTNM status were retrieved from medical reports. Follow-up was available until August 2009. The study was approved by the local ethics committee.

Basic patient demographical data are summarised in [Table 1](#tbl1){ref-type="table"}.

Tissue microarray construction
------------------------------

Tissue microarray (TMA) blocks were constructed as described previously ([@bib8]), with a manual microarrayer (Beecher Instruments, Sun Prairie, WI, USA) to include twelve cores (600-*μ*m diameter) from each CRC case. Six cores were obtained from the central part of the tumour and six cores from the invasion front.

Immunohistochemistry for mismatch repair proteins and its evaluation
--------------------------------------------------------------------

Standard immunohistochemistry was applied to 5-*μ*m thick sections to display MLH1, MSH2, MSH6 and PMS2 expression, using antibodies against MLH1 (Menarini, Zaventem, Belgium; clone ES05, dilution 1 : 100), MSH2 (Menarini; clone 25D12, dilution 1 : 200), MSH6 (Menarini; clone PU29, dilution 1 : 400) and PMS2 (Menarini; clone M0R4G, dilution 1/100), and was performed on the BOND-MAX (Leica, Wetzlar, Germany). Briefly, the immunohistochemical expression was visualised using the Bond Polymer Refine Detection kit (Menarini; kit DS9800). The sections were counterstained with haematoxylin.

Mismatch repair (MMR) protein expression was divided into 'intact\' and 'deficient\' groups. Intact MMR protein expression was defined by nuclear expression of MLH1, MSH2, MSH6 and PMS2 in neoplastic epithelial cells ([@bib32]). If stromal cells were negative for at least one of these markers, the case was considered non-evaluable for MMR protein expression by lack of positive internal control.

Immunohistochemistry for FHL2 and its evaluation
------------------------------------------------

Standard immunohistochemistry was applied to 5-*μ*m thick sections to display FHL2 expression, using a specific antibody provided by Abcam (Cambridge, UK; ab66399, dilution 1 : 200) and was performed on the BOND-MAX. Briefly, the immunohistochemical expression was visualised using the Bond Polymer Refine Detection kit. The sections were counterstained with haematoxylin.

We used the NanoZoomer 2.0-HT slide scanner (Hamamatsu, Louvain-La-Neuve, Belgium) for TMA core image acquisition and the NDP viewer software (Hamamatsu) to visually assess slides and image quality. Only the cores satisfying all the control steps were considered for staining evaluation as follows. In each core, the neoplastic epithelial cells were surrounded by a pathologist (LV) to study FHL2 expression specifically in them. A quantitative analysis was then performed using the Visiomorph software package (Visiopharm, Hoersholm, Denmark) to determine the labelling index (LI), which is the percentage of the immunostained-tissue area within the epithelial compartment. This evaluation was performed for each TMA core and pooled per patient by distinguishing central tumour part from invasion front, as detailed elsewhere ([@bib8]). To ensure representativeness, only reference regions for which at least two cores could be evaluated were included for further analysis.

Immunohistochemistry for E-cadherin and *β*-catenin and its evaluation
----------------------------------------------------------------------

Immunohistochemical stainings for FHL2 and for the EMT-markers E-cadherin and *β*-catenin were performed on consecutive 5-*μ*m thick sections of 10 randomly chosen CRC resection specimens. For FHL2, staining was performed as described above. For E-cadherin and *β*-catenin, we used antibodies provided by Dako (Glostrup, Denmark; NCH-38, dilution 1 : 100; *β*-catenin 1, dilution 1 : 300). Stainings were performed on the BOND-MAX. Briefly, the immunohistochemical expression was visualised using the Bond Polymer Refine Detection kit for E-cadherin, and the Bond Intense R Detection kit (Menarini; kit DS9263) for *β*-catenin. The sections were counterstained with haematoxylin. The consecutive slides were evaluated by two pathologists (LV and PDM) using an Olympus BX50 microscope (Olympus Belgium, Aartselaar, Belgium).

Cell cultures and transfections
-------------------------------

hTERT-immortalised human colon tumour-derived myofibroblasts ([@bib6]) were maintained in DMEM (Invitrogen, Gent, Belgium) supplemented with 10% foetal bovine serum and antibiotics. Small-interfering RNA (siRNA)-targeting FHL2 (5′-AAG GTA ATG ACC AGT TGT TAT-3′) and scrambled RNAi-negative control (Qiagen, Venlo, The Netherlands) were transfected by electroporation (Cell line nucleofector kit V, Lonza, Basel, Switzerland).

Immunocytochemistry and western blot on cultured cells
------------------------------------------------------

For immunocytochemistry, pellets of hTERT-immortalised myofibroblasts were fixed in 4% buffered formol for 12 h, followed by a wash with PBS and transfer to 70% ethanol, and then embedded in paraffin, sectioned, and stained with the anti-FHL2 antibody. For counterstaining, haematoxylin was used.

For western blot analysis, hTERT-immortalised myofibroblasts (1--10 × 10^6^) were harvested in Laemmli lysis buffer (0.125 ℳ Tris--HCl (pH=6.8), 10% glycerol, 2.3% SDS). Cell lysates (25 *μ*g) were suspended in 10 *μ*l reducing sample buffer (1 ℳ Tris--HCl (pH=6.8), 30% glycerol, 6% SDS, 3% *β*-mercaptoethanol, 0.005% bromophenol blue) and boiled for 5 min at 95 °C. Samples were subjected to SDS--PAGE gels, transferred to PVDF membranes, blocked in 5% non-fat milk in PBS with 0.5% Tween-20 and immunostained. The anti-FHL2 antibody as well as a mouse monoclonal anti-tubulin (Sigma-Aldrich, St. Louis, MO, USA) were used.

Statistical analysis
--------------------

Multivariate survival analyses were performed using the standard Cox regression. We first analysed the set of clinicopathological variables presented in [Table 1](#tbl1){ref-type="table"} and then selected those showing a contribution characterised by a *P*-value\<0.05. We then added the FHL2 LI to the 'clinical\' model to test its potential prognostic contribution with development of metastases and mortality as outcome parameters; time to development of metastases was calculated as the time between surgical intervention and detection of metastases on imaging grounds, and the time to mortality as time between surgery and death, as registered at the community level. This prognostic impact was also illustrated by means of the standard Kaplan--Meier analysis and the Wilcoxon--Gehan test.

Four-and-a-half LIM domains protein 2 expression in the tumour invasion front and in the tumour centre was considered separately.

For each statistical analysis, the cases presenting missing value(s) in the concerned variable(s) were omitted.

Results
=======

Study population
----------------

Tumour samples from 296 cases could be included; clinical and histopathological data are presented in [Table 1](#tbl1){ref-type="table"}. Final analysis for FHL2 expression could be performed for the tumour invasion front of 167 patients, and for the tumour centre of 249 patients.

FHL2 expression in CRCs
-----------------------

We studied the expression of FHL2 using a validated anti-FHL2 antibody ([Figure 1](#fig1){ref-type="fig"}) and observed varying degrees of cytoplasmic FHL2 expression by neoplastic epithelial cells in all cases ([Figure 2](#fig2){ref-type="fig"}) in the invasion front as well as in the centre of the tumour. This cytoplasmic expression was often more prominent at the cellular periphery. Nuclear FHL2 expression was not observed.

In addition, cytoplasmic FHL2 expression could be detected in elongated, mesenchymal-appearing cells of the tumour stroma.

Prognostic evaluation of FHL2 expression
----------------------------------------

Using multivariate survival analyses, we first identified the clinicopathological variables with impact on prognosis in the complete case series of 296 CRC patients. The results showed that age and N stage are independent negative prognostic factors for overall survival, and female gender and N stage for the development of metachronous metastases (data not shown). Taking these factors into account, we identified higher FHL2 expression at the tumour invasion front as well as at the tumour centre being an independent negative prognostic factor (both with *P*\<0.001, see [Table 2](#tbl2){ref-type="table"}), associated with the development of metachronous metastases. Moreover, FHL2 expression in the tumour invasion front was also associated with overall survival independently of the clinicopathological variables (*P*\<0.05, see [Table 2](#tbl2){ref-type="table"}).

By analysing the distribution of the FHL2 LI values in order to stratify the patients in relation to their metastasis-free survival, we found that \<20% of the patients with a LI ⩽40% in the tumour invasion front or in the tumour centre had a short metastasis-free survival (in contrast to patients with LI\>40%, see [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The Kaplan--Meier curves shown in [Figure 3B and C](#fig3){ref-type="fig"} confirm the significant prognostic value of this FHL2 threshold for the invasion front and the centre, respectively, (both with *P*\<0.001). [Figure 3A](#fig3){ref-type="fig"} also demonstrates the significant prognostic value of this threshold for the invasion front with regard to overall survival (*P*\<0.01). A similar result was obtained for FHL2 expression in the tumour centre (data not shown); however, this expression is not an independent prognostic factor (see [Table 2](#tbl2){ref-type="table"}).

Expression of FHL2 in relation to E-cadherin and *β*-catenin
------------------------------------------------------------

In a pilot experiment including 10 cases, foci of intense FHL2 expression with concomitant reduced E-cadherin expression and appearance of nuclear expression of *β*-catenin could be demonstrated in consecutive sections. These foci were found in EMT areas, characterised by poor differentiation of the cancer, and presence of small clusters of cancer cells and isolated cancer cells in the extracellular matrix-rich peritumoural stroma ([Figure 4](#fig4){ref-type="fig"}).

Discussion
==========

In this study, we demonstrated that higher FHL2 expression in malignant epithelial cells correlates with progressive disease in patients with CRC, suggesting that FHL2 is an independent and reliable prognostic indicator for the development of metachronous metastases and for overall survival in this type of cancer. This is consistent with the finding that FHL2 promotes invasive potential in colon cancer ([@bib45]).

During cancer progression, advanced tumour cells frequently exhibit a conspicuous downregulation of epithelial markers and a loss of intercellular junctions, resulting in a loss of epithelial polarity and reduced intercellular adhesion. These alterations are often accompanied by nuclear accumulation of *β*-catenin, increased cell motility and expression of mesenchymal-specific proteins such as vimentin ([@bib39]; [@bib17]; [@bib38]; [@bib18]). This process called EMT can therefore promote invasion and metastasis ([@bib1]; [@bib17]; [@bib38]).

One of the decreased epithelial markers during EMT is E-cadherin ([@bib7]). Four-and-a-half LIM domains protein 2 negatively regulates the transcription of E-cadherin through interaction with Snail 1 ([@bib45], [@bib46]). Moreover, FHL2 stimulates vimentin and matrix metalloproteinase-9 expressions ([@bib45]). Other arguments for a role of FHL2 in EMT come from a gain-of-function experiment in which the overexpression of FHL2 in a fish pre-osteoblastic cell line promoted cell dedifferentiation and altered gene expression profile in agreement with an EMT-like phenotype ([@bib31]). In contrast to others ([@bib45]), we did not detect nuclear FHL2 expression in CRC, using a well-defined and validated antibody; therefore, we suggest that FHL2 interacts via cytoplasmic/cell periphery protein interactions, rather than via direct transcriptional activation or repression, in the progression of CRC, including EMT.

Multiple functions have been ascribed to FHL2, and it is puzzling how a protein that consists of LIM domains only and that lacks any obvious enzymatic activity can exert such a functional diversity. Four-and-a-half LIM domains protein 2 can interact with \>50 different proteins that belong to different functional classes, including receptors ([@bib24]; [@bib27]), structural proteins ([@bib25]; [@bib5]), transcription factors and cofactors ([@bib34]; [@bib14]; [@bib16]), splicing factors ([@bib9]; [@bib30]), DNA replication and repair enzymes ([@bib4]; [@bib44]), and enzymes ([@bib20]; [@bib25]; [@bib41]). The biological importance of many of these protein--protein interactions has not been determined, but such information will contribute to further clarifying the roles of FHL2 in colorectal and other cancers. Cell-specific expression and cell-specific subcellular distribution of FHL2, as well as the available concentrations of the interacting partners may partially favour certain interactions. The abundance of extracellular matrix in EMT areas do suggest that following integrin engagement, FHL2 localises to focal adhesions.

Our study does not allow identification of molecular mechanisms behind FHL2 upregulation in CRC, which may be the result of nonspecific deregulation of gene expression as a characteristic of a more aggressive tumoural phenotype. It is, however, noteworthy that computer analysis of the FHL2 promoter revealed a plethora of putative transcription factor-binding sites ([@bib15]), suggesting a complex transcriptional regulation.

In our series, fibroblasts within carcinoma tissue also showed FHL2 expression, thereby confirming results from a study specifically investigating FHL2 in peritumoural fibroblasts ([@bib13]). In that study, FHL2 expression in peritumoural fibroblasts correlated with lymphatic metastasis in sporadic CRC but not in CRC with mutation in *MMR* genes; in the present work, we did not study any possible link between MMR protein and FHL2 expression, given the low number of cases in which defective MMR protein expression had been demonstrated.

Our results also suggest that FHL2 blockade could be an effective therapeutic approach in selected CRC patients. Four-and-a-half LIM domains protein 2 is a LIM protein that mediates protein--protein interactions and is found in focal adhesions where it functions as an interacting hub to bind focal adhesion kinase (FAK) and others, possible substrates of FAK ([@bib11]). A crucial event in integrin-mediated signal transduction is the phosphorylation of proteins on tyrosine residues, mainly mediated by the FAK. Several companies have designed specific inhibitors of FAK activity (e.g. GSK2256098); these are currently in clinical trials and have the potential to inhibit downstream events of FHL2-mediated signalling ([@bib36]). Other approaches are pharmacological targeting of downstream signalling initiated by FHL2; examples are Wnt signalling ([@bib2]) and TGF-*β* signalling ([@bib43]). Moreover, *in vitro* experiments have shown that blocking FHL2 expression by siRNA could inhibit the growth and proliferation of human CRC cells ([@bib19]); in that study, chitosan-based siRNA nanoparticles were a very efficient delivery system for siRNA *in vivo*. The efficacy in human CRC remains, however, to be clarified.

In conclusion, we showed using a validated antibody that CRC patients with high FHL2 protein levels in neoplastic epithelium have a significantly higher probability of developing metachronous metastases and have a shorter overall survival, indicating a prognostic and contributing role of FHL2 in this tumour. Although conducted on a large population, our study is retrospective and monocentric; thus, our data need to be confirmed by prospective independent series. We suggest that targeting of FHL2 may have a promising role in the management of CRC; further research unravelling the molecular mechanisms behind our observation is, however, warranted.
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![Western blot analysis (upper) and imunocytochemistry (lower) of FHL2 protein expression in hTERT-immortalised myofibroblasts after transfection with siRNA-targeting FHL2 and scrambled RNAi-negative control, confirming thereby the specificity of the FHL2 antibody used in this work (magnification × 200). Inserts show details of FHL2 expression.](bjc2013290f1){#fig1}

![Four-and-a-half LIM domains protein 2 expression in neoplastic epithelial cells and fibroblasts. Diffuse (left) and focal (right) positivity in neoplastic epithelium (magnification × 200).](bjc2013290f2){#fig2}

![Prognostic value of FHL2 expression. (**A**) Overall survival curve of patients dichotomised on the basis of the FHL2 LI evaluated in tumour invasion front (*P*\<0.01). (**B** and **C**): Metastasis-free survival curves of patients dichotomised on the basis of the FHL2 LI evaluated in (**B**) tumour invasion front (*P*\<0.001) and (**C**) tumour centre (*P*\<0.001). Complete and censured data are shown by dots and crosses, respectively.](bjc2013290f3){#fig3}

![Consecutive sections with foci of (upper left) intense FHL2 expression with concomitant (upper right) reduced E-cadherin expression and (lower) appearance of nuclear expression of *β*-catenin (arrows) in areas of EMT. Note the lower FHL2 expression as well as the stronger E-cadherin expression and the absence of nuclear *β*-catenin expression in adjacent well-differentiated tumour glands (\*\* magnification × 400).](bjc2013290f4){#fig4}

###### Clinical and histopathological patient data

  **Patient characteristics**                                                           **Tumoural centre**                 **Tumoural front**
  ----------------------------------------- ----------------------------------- ----------------------------------- -----------------------------------
  *n*                                                       296                                 249                                 167
  Sex ratio (female:male)                            0.82 (133 : 163)                    0.81 (112 : 137)                     0.94 (81 : 86)
  Mean age (min--max)                                   68 (27--92)                         68 (27--92)                         68 (35--92)
  **TNM** **status**                                                                                                
  T1                                                     14 (4.7%)                           11 (4.4%)                           8 (4.8%)
  T2                                                     53 (18%)                           47 (18.9%)                          32 (19.2%)
  T3                                                    212 (71.6%)                         179 (71.9%)                         119 (71.2%)
  T4                                                     17 (5.7%)                           12 (4.8%)                           8 (4.8%)
  N0                                                    173 (58.4%)                         145 (58.2%)                         96 (57.5%)
  N1                                                    89 (30.1%)                           77 (31%)                           51 (30.5%)
  N2                                                    34 (11.5%)                          27 (10.8%)                           20 (12%)
  Intact/defective MMR protein expression    261/20[a](#t1-fn1){ref-type="fn"}   230/14[b](#t1-fn2){ref-type="fn"}   152/10[b](#t1-fn2){ref-type="fn"}

Abbreviation: MMR=mismatch repair.

Fifteen cases could not be evaluated for MMR protein expression.

Five cases could not be evaluated for MMR protein expression.

###### Multivariate analysis of overall survival and metastasis-free survival

  **Tumoural centre (*n*=249)**    **Tumoural front (*n*=167)**                                                                            
  ------------------------------- ------------------------------ ------- ------------- --------- --------- --------- ------- ------------- ---------
  **Overall survival**                                                                                                                     
  0.00000                                      Age               1.03    1.01--1.05    0.00041   0.00000      Age    1.05    1.02--1.07    0.00004
                                               *N*               1.91    1.52--2.40    0.00000                *N*    2.54    1.89--3.40    0.00000
                                             FHL2 LI             1.87    0.71--4.96    0.20612              FHL2 LI  3.38    1.24--9.21    0.01747
  **Metastasis-free survival**                                                                                                             
  0.00000                                      Male              0.62    0.39--0.99    0.04326   0.00000     Male    0.40    0.22--0.73    0.00285
                                               *N*               2.69    1.99--3.65    0.00000                *N*    3.26    2.28--4.67    0.00000
                                             FHL2 LI             12.25   3.29--45.61   0.00019              FHL2 LI  11.51   3.23--41.05   0.00016

Abbreviations: CI=confidence interval; FHL2=four-and-a-half LIM domains protein 2; HR=hazard ratio; LI=labelling index.

Cox proportional-hazards regression model: model *P*-value indicates the overall level of significance of the multivariate model; the individual *P*-values represent the levels of significance of the independent contributions of each variable (where *N* takes the values: 0, 1 and 2).
